Close Menu


News on in vitro diagnostics for gastrointestinal disease.

The test runs on the firm's Curian rapid fluorescent immunoassay and detects four species of a common foodborne pathogen.

The blood test is the lead product for the Palo Alto, California-based company, which in 2018 purchased the assets of defunct proteomics outfit Applied Proteomics.

The partners will assess Stella's assay by quantifying proto-oncogenes in Barrett's esophagus tissue that have progressed to cancer, and those that have not.

The company is focused on developing and commercializing therapeutic and companion diagnostic products to treat inflammatory bowel disease.

The fecal calprotectin test, which runs on the company's ProciseDx immunoassay system, is designed to help in the diagnosis of Crohn's disease and ulcerative colitis.